RBC bullish on OVID's 2020 catalysts [Seeking Alpha]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Seeking Alpha
Seeking Alpha Healthcare | On the Move RBC bullish on OVID's 2020 catalysts Nov. 29, 2019 7:27 AM ET Ovid Therapeutics Inc. (OVID) Brandy Betz RBC Capital analyst Brian Abrahams sees a favorable risk-reward for Ovid Therapeutics (NASDAQ: The key data catalysts will be for lead programs OV101 and soticlestat. Data for OV101 for FXS should report in Q1, and the pivotal Phase 3 trial for Angelman's Syndrome will report in mid-2020. Abrahams says "there are underappreciated signals of efficacy" for the latter indication that could provide a "low regulatory bar" for the disease. The analyst thinks OV101 could generate $450M+ in "peak annual out-year revenue if successful." For soticlestat, he sees a near $400M out-year sales opportunity for refractory epilepsies. RBC maintains an Outperform rating and $12 price target. OVID has a Very Bullish average Sell Side rating OVID shares are up 4.3% See all stocks on the move » Now read: Qiagen: From Bad Results To Potential Acquisition Target »
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at Citigroup Inc. from $4.00 to $3.50. They now have a "neutral" rating on the stock.MarketBeat
- Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at B. Riley. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]Yahoo! Finance
- We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
OVID
Earnings
- 3/8/24 - Miss
OVID
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- OVID's page on the SEC website